These post hoc analyses were conducted on the pooled 3-week data of the subset of patients diagnosed with a mixed episode
according to DSM-IV-TR, and complemented by the data collected during the 9-week extension trial.
Ruling out a mixed episode
poses the greatest challenge in differentiating BPD from bipolar disorder.
The drug is already approved for the treatment of schizophrenia and short-term treatment of acute manic or mixed episodes
associated with bipolar I disorder in adults and the treatment of irritability associated with autistic disorder in children and adolescents 5-16 years old.
and jointly developed and commercialized by Otsuka and Bristol-Myers Squibb, ABILIFY is the first and only available dopamine partial agonist and is indicated for the acute treatment of manic or mixed episodes
associated with Bipolar I Disorder in adults and pediatric patients (ages 10-17), the maintenance treatment of Bipolar I Disorder, treatment of Schizophrenia in adults and adolescents (ages 13-17), and as an adjunctive treatment to an antidepressant in adults with Major Depressive Disorder who have an inadequate response to antidepressant therapy.
The subjects also had a history of one or more manic or mixed episodes
that had been severe enough to require hospitalization and / or treatment with a mood stabilizer or antipsychotic.
Events included hypomanic, manic, or mixed episodes
(36%); alcohol or drug dependence lapses (32%); and major depression or subsyndromal depressive symptoms (21%).
People with bipolar disorder also may experience mixed episodes
, marked by symptoms of mania and clinical depression occurring simultaneously.
By DSM-IV standards, mixed episodes
must satisfy criteria for both manic and depressive episodes and are relatively rare in bipolar disorder, but not everyone goes by this definition.
The study began with a stabilization phase involving 567 bipolar disorder patients with a recent manic or mixed episode
who received open-label aripiprazole at 15 or 30 mg/day for 6-18 weeks.
com for more information on this once daily option for the acute treatment of manic or mixed episodes
associated with bipolar I disorder and for the treatment of schizophrenia in adults.
The Food and Drug Administration has approved cariprazine, an atypical antipsychotic, for the acute treatment of manic or mixed episodes
in bipolar I disorder and schizophrenia in adults.
It is explained that Divalproex sodium extended-release tablets USP 250 mg and 500 mg is the generic equivalent of AbbVie Inc s Depakote ER extended-release tablets, 250 mg and 500 mg respectively and indicated for the treatment of acute manic or mixed episodes
associated with bipolar disorder, with or without psychotic features.